The State of the Microbiome

Table of Contents
1 Study Design
1.1 Background, Objectives, and Design
1.2 Respondent Mix - Geography
1.3 Respondent Mix - Seniority Level and Company Size
2 Executive Summary
2.1 Executive Summary
3 Microbiome Investment
3.1 Gastroenterology and Infectious Disease Mark the Most Active Therapy Areas
3.2 Infectious Disease and Gastroenterology Most Highly Invested Therapy Areas
3.3 A Closer Look at the Microbiome Pipeline
3.4 Microbiome Pipeline Targeting Gastrointestinal Indications and Infectious Diseases
3.5 A Closer Look at the Microbiome Pipeline Targeting Gastrointestinal Indications
3.6 A Closer Look at the Microbiome Pipeline Targeting Infectious Diseases
4 Challenges with Developing Microbiome Therapeutics
4.1 Identifying the Mechanism of Action Seen as a Major Challenge
4.2 Identifying the Mechanism of Action Is Seen as the Most Challenging Factor
4.3 A Closer Look by Seniority Level
5 Challenges with Launching Microbiome Therapeutics
5.1 Manufacturing Identified as a Major Challenge
5.2 Manufacturing Identified As the Most Challenging Factor
5.3 A Closer Look by Seniority Level
6 Challenges with Manufacturing Microbiome Therapeutics
6.1 Dose Formulation Is a Major Challenge
7 Key Findings and Recommendations
7.1 Summary of Key Findings
7.2 Recommendations
8 Appendix
8.1 Related Reports
8.2 Abbreviations
8.3 Primary Research
8.4 About the Authors
8.5 About Thematic Research
8.6 About GlobalData
8.7 Contact Us
8.8 Disclaimer